Starpharma has developed a pipeline of novel DEP^® oncology products. Its clinical-stage assets, DEP^® SN38, DEP^® cabazitaxel, and DEP^® docetaxel, are dendrimer-based chemotherapeutic drugs that have demonstrated improvements in efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP^® radiopharmaceuticals and DEP^® Antibody-Drug Conjugates (ADCs) in development.